Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma

Archives of Gynecology and Obstetrics

Volumn 289, Issue 2, 2014, Pages 393-398

  Kucukgoz Gulec, Umran ^a   Gumurdulu, Derya ^a   Guzel, Ahmet Baris ^a   Paydas, Semra ^a   Seydaoglu, Gulsah ^a   Acikalin, Arbil ^a   Khatib, Ghanim ^a   Zeren, Handan ^a   Vardar, Mehmet Ali ^a   Altintas, Aytekin ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Epithelial ovarian cancer; Ki 67; Platinum resistance; Prognosis; Survivin; Topoisomerase II

Indexed keywords

BIRC5 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; INHIBITOR OF APOPTOSIS PROTEIN; KI 67 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; CANCER GRADING; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84895129385     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-3000-z     Document Type: Article

References (25)

1. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462
2. Hickman JA (1992) Apoptosis induced by anticancer drugs. Cancer Metast Rev 11:121-139
3. Salvesen GS, Duckett CS (2002) Apoptosis: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410 (Pubitemid 34685698)
4. Li F (2003) Survivin study: what is the next wave? J Cell Physiol 197:8-29 (Pubitemid 37486223)
5. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921 (Pubitemid 27353455)
6. Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K, Kanda K, Yamaguchi H, Akise D, Hung YC, Ueki M (2002) Survivin gene expression in endometriosis. J Clin Endocrinol Metab 87(7):3452-3459 (Pubitemid 34816403)
7. Kanno R, Yamakava H, Utsunomiya H, Ito K, Sato S, Yajima A (2006) Expression of survivin and Bcl-2 in the normal endometrium. Mol Human Repr 6:529-534
8. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG (2002) Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59:1406-1412
9. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki- 67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalinfixed paraffin sections. J Pathol 168:357-363 (Pubitemid 23013251)
10. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440 (Pubitemid 34685700)
11. Gotlieb WH, Goldberg I, Weisz B, Davidson B, Novikov I, Kopolovic J, Ben- Baruch G (2001) Topoisomerase II immunostaining as prognostic marker for survival in ovarian cancer. Gynecol Oncol 82:99-104 (Pubitemid 32634960)
12. Brustmann H (2004) Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase IIα and prognosis. Gynecol Oncol 95:16-22 (Pubitemid 39286272)
13. Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A, Scambia G (2008) Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients. Br J Cancer 98:1910-1915 (Pubitemid 351821572)
14. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers FIGO Committee on gynecologic oncology. Int J Gynecol Obstet 70:209-262
15. Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L, Gessi M, Gallotta V, Scambia G (2005) Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 92:271-277 (Pubitemid 40343140)
16. Li F, Yang J, Ramnath N, Javle MM, Tan D (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114(4):509-512 (Pubitemid 40349608)
17. Kleinberg L, Florenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B (2007) Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 109:228-238 (Pubitemid 46106237)
18. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R (2003) Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 16(6):574-583 (Pubitemid 36718439)
19. Kar R, Sen S, Singh A, Sharma H, Kumar S, Gupta SD, Singh N (2007) Role of apoptotic regulators in human epithelial ovarian cancer. Cancer Biol Ther 6(7):1101-1105 (Pubitemid 351574963)
20. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S (2001) Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 19:537-542
21. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M (2002) Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21:315-320
22. Mita S, Nakai A, Maeda S, Takeshita T (2004) Prognostic significance of Ki-67 antigen immunostaining (MIB-1 monoclonal antibody) in ovarian cancer. J Nippon Med Sch 71(6):384-391 (Pubitemid 40143957)
23. Kommoss S, du Bois A, Schmidt D, Parwaresch R, Pfisterer J, Kommoss F (2006) Chemotherapy may be more effective in highly proliferative ovarian carcinomas-a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Gynecol Oncol 103:67-71 (Pubitemid 44389863)
24. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum Era: a meta-analysis. J Clin Oncol 20(5):1248-1259 (Pubitemid 34177431)
25. Chekerov R, Klaman I, Zafrakas M, Konsgen D, Mustea A, Petschke B, Lightenegger J, Dahl E (2006) Altered expression pattern of Topoisomerase IIα in ovarian tumor epithelial and stromal cells after platinum based chemotherapy. Neoplasia 8(1):38-45